Curis Announces Presentations at American Association for Cancer Research Annual Meeting 2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 9, 2009 - Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation proprietary targeted medicines for cancer treatment, today announced that it will present data on one of its proprietary oncology programs at the upcoming American Association for Cancer Research (AACR) 100th Annual Meeting to be held in Denver, CO at the Colorado Convention Center on April 18-22.
Curis scientists will make two presentations related to CUDC-305, the Company's orally available, synthetic small molecule Hsp90 inhibitor. CUDC-305 has recently completed GLP-toxicology testing and data suggests that CUDC-305 has a favorable safety profile. The Company anticipates filing an IND application for CUDC-305 in mid-2009 and is currently involved in discussions with pharmaceutical and biotechnology companies regarding a potential collaboration for this compound. Curis is seeking to consummate such a collaboration in mid-2009.
The presentations are as follows:
| Sunday, April 19, 2009, 3:40 p.m. - 3:55 PM
|
| Location: Room 708-712, Colorado Convention Center |
| Session: Minisymposium on Novel Targeted Agents (minisymposium runs from 2:00 p.m. to 5:30 p.m.) |
| Presentation Title: Antitumor activity of CUDC-305, a novel oral Hsp90 inhibitor, in solid and hematological tumor xenograft models
|
| Presenter: Rudi Bao, M.D., Ph.D. Director, Oncology |
| Tuesday, April 21, 2009, 1:00 p.m. - 5:00 PM
|
| Location: Hall B-F, Colorado Convention Center, Poster Session 37 |
| Session: Novel Agents 3 |
| Presentation Title: A novel tumor-specific Hsp90 inhibitor with long lasting biological activity |
| Presenter: Jing Wang, Ph.D., Scientist II |
| Poster Section/Board Number: 37/14 |
| Abstract Number: 4689 |
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines for cancer. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.
Cautionary Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding Curis' belief that it will be able to consummate a collaboration related to CUDC-305 in mid-2009 and the Company's belief that the compound has a favorable safety profile. The Company may use words such as “believes”, “expects”, “anticipates”, “plans”, “seeks”, “estimates”, “will”, “may” or similar expressions to identify these forward-looking statements. There are important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. The Company faces risk factors identified in the Annual Report on Form 10-K for the year ended December 31, 2008 and other filings that it periodically makes with the Securities and Exchange Commission.
In addition, any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing the views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise.
Contact: Curis, Inc.
Michael P. Gray, 617-503-6632
Chief Financial Officer
mgray@curis.com
